Introduction {#sec1_1}
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Angioimmunoblastic T-cell lymphoma (AITL) is a rare subtype of peripheral T-cell lymphoma \[[@B1], [@B2]\]. It accounts for 15--20% of all peripheral T-cell lymphomas and usually affects individuals in the seventh decade of life \[[@B3], [@B4], [@B5]\]. Approximately 20% of patients have associated autoimmune phenomena, such as circulating immune complexes, cold agglutinins, hemolytic anemia, rheumatoid factor and anti-smooth muscle antibodies \[[@B1]\]. AITL is a primary CD4 T-cell disorder with B-cell and endothelial cell dysregulation \[[@B4]\]. The clinical features include generalized lymphadenopathy, hepatosplenomegaly and B symptoms, including weight loss, fever and night sweats. The diagnosis is usually made by lymph node biopsy \[[@B6]\]. Skin involvement occurs in up to 50% of patients, but has not been well characterized \[[@B4], [@B7]\]. We present a case of AITL with prominent skin findings.

Case Report {#sec1_2}
===========

A 55-year-old female patient with a history of hypothyroidism presented with a 2-year history of an intermittent itchy rash that started on her neck and progressed to her arms, chest, abdomen and back. The patient was treated with oral prednisone and topical steroids which initially improved the lesions; however, they recurred with discontinuation of these medications.

Physical examination revealed multiple 2--4-mm erythematous, blanchable macules and papules on her trunk and extremities (fig. [1](#F1){ref-type="fig"}). She also had bilateral arthritis of the interphalangeal joints of the hands, wrists, elbows and knees as well as multiple enlarged axillary and inguinal lymph nodes. She presented with hypereosinophilia with an absolute count of 47,600/μl. Bone marrow aspirate showed hypercellularity, with a myeloid:erythroid ratio of 5:1; 65% of the cells were eosinophilic precursors with normal maturation. Eight-color flow cytometry revealed a population of immature T cells comprising 10.4% of total white blood cells with the following markers: CD3+, CD4--, CD5+, CD7+ dim, CD8--, CD34--, CD45+ and TdT--. A lesional skin biopsy reported T-cell lymphoma (diffusely positive CD3, CD4 and CD5 cells and focally positive CD8 and TIA-1 cells) (fig. [2](#F2){ref-type="fig"}). An axillary lymph node biopsy was consistent with AITL (CD3, CD4, CD5, CD7 and Epstein-Barr virus positive and CD8 and CD10 negative, with a CD21+ dendritic cell expansion) (fig. [3](#F3){ref-type="fig"}). A CT scan of the chest and abdomen was negative for mediastinal or abdominal adenopathy.

The diagnosis of an AITL, Cotswolds stage IVAD was made, with a Prognostic Index for AITL score of 1 (as described by Federico et al. \[[@B1]\]). Six cycles of CHOP-21 chemotherapy in addition to thalidomide 50 mg/day from days 1 to 21 were administered. Complete remission was achieved, as documented by a CT scan 4 weeks after cycle 6.

Discussion {#sec1_3}
==========

In 1974, Frizzera et al. \[[@B8]\] described AITL as a reactive lymphoproliferative disorder of T lymphocytes. In 2001, the WHO classification of tumors of hematopoietic and lymphoid tissue listed AITL as a peripheral T-cell lymphoma \[[@B3], [@B4]\].

The pathogenesis of AITL remains unclear. In some cases the disease is preceded by an allergic reaction, infection or drug exposure \[[@B2], [@B6]\]. A primary monoclonal and polyclonal T-cell proliferation secondary to Epstein-Barr virus infection also been suggested \[[@B9]\].

At the time of diagnosis, almost all patients present with advanced-stage disease (stages III--IV). In 70% of patients manifestations include B symptoms, and 79% have splenomegaly \[[@B8], [@B10]\]. Cutaneous lesions vary widely and can be encountered in approximately half of cases, presenting as a nonspecific rash, usually macules and papules, and less commonly purpura, urticaria, nodules or petechiae \[[@B7]\].

The differential diagnoses include infections, inflammatory or autoimmune diseases and other lymphoid neoplasms. A diagnosis can only be achieved by lymph node biopsy \[[@B6]\].

A variety of regimens have been used for the treatment of AITL. Among these, anthracycline-based therapy is considered the first-line treatment \[[@B11]\]. Patients treated with this regimen achieve complete remission in 61% of cases, with a 5-year overall survival rate of 32% and a recurrence-free survival of only 18% \[[@B1]\]. When high-dose chemotherapy followed by autologous stem cell transplantation is administered, the likelihood of complete remission is improved \[[@B12], [@B13]\].

The molecular profile of the neoplastic T cells in AITL consists of CXCL13, bcl-6 and CD40L, shown in gene expression studies \[[@B6]\]. 95% of AITL cases had increased expression of at least one of the following markers: SLAM-associated protein, programmed death-1 and c-Maf \[[@B14]\].

The diagnosis of AITL is very challenging, given the lack of clinical and histological diagnostic criteria. In one of the largest series of cases of peripheral T-cell lymphomas \[[@B1]\], agreement on diagnosis by expert hematopathologists was only 81%. Cutaneous and histological findings may be nonspecific; therefore, clinical history, symptoms and complementary studies are very important. Our patient had been recently diagnosed with autoimmune hemolytic anemia, hypereosinophilic syndrome and arthritis; these, along with her signs and symptoms and besides skin and lymph node biopsies, led us to the correct diagnosis.
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![Immunohistochemical staining of an axillary lymph node biopsy. CD3, CD4, CD5, CD7 and Epstein-Barr virus (VEB) were positive and CD8 and CD10 negative, with a CD21+ dendritic cell expansion.](cde-0006-0291-g03){#F3}
